NEWS

Company Overview


PhenoNet, Inc. | Cambridge, MA | Founded 2023


Mission: To discover, develop, and commercialize innovative, patient-profile-driven therapies for neurodegenerative diseases, focusing on Alzheimer Disease (AD) and Amyotrophic Lateral Sclerosis (ALS).


Lead Clinical Program


Program: PHENOGENE-1A for ALS


Drug Candidate: PHENOGENE-1A (Cromolyn Inhalation Formulation)


Indication: Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)


Regulatory Status: FDA authorization to proceed with a Phase IIB clinical study


Study Design Highlights


Target Enrolment: 105 patients across multiple sites over ~18 months


Treatment Duration: 24 weeks (BID dosing) + 4-week safety follow-up


Primary Endpoint: Change from baseline to Week 24 in ALSFRS-R (ALS Functional Rating Scale-Revised)


Secondary Endpoints: Combined Assessment of Function and Survival (CAFS), pulmonary function, and exploratory biomarkers


Mechanism of Action


Cromolyn is a multi-functional compound with established neuroprotective properties. Its therapeutic effects include:


· Stabilization of mast cells and inhibition of microglial activation


· Suppression of proinflammatory cytokines and chemokines


· Reduction of neuroinflammation and fibrotic scarring


· Positive preclinical results in ALS animal models and encouraging signals in a small human cohort

Pipeline Highlights


PHENOGENE-1A


· Repurposed, IP-protected cromolyn formulation


· Optimized for central nervous system (CNS) delivery


· Focused on early-stage neurodegeneration and functional preservation


PhenoCNU (Preclinical)


· A next-generation, dual-activity compound


· Combines anti-neuroinflammatory activity with ligand-receptor targeting

· Under evaluation for both ALS and Alzheimer Disease


What Sets PhenoNet Apart


· Patient Profile Targeting: Using genomic and biomarker data to tailor interventions


· Safe, Multi-Functional Agents: Based on well-characterized compounds with novel delivery strategies


· Focus on Early Intervention: Targeting the disease before irreversible neurological damage


· Dual Emphasis: Combining quality-of-life enhancement with long-term disease modification

Contact


For inquiries, please contact:


Info@phenonet.us


📞 +1 (617) 784-0490



Key Scientific Publications

1. Cromolyn Inhibits Proinflammatory Cytokine Secretion by Human Microglia (HMC3) Nature Scientific Reports, 2021

2. Cromolyn Suppresses Fibrosis and Inflammation, Enhances Microglial Function and Neurite Outgrowth Nature Scientific Reports, 2021

3. Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions PubMed

4. Oral inhaled cromolyn for mild-to-moderate amyotrophic

Lateral sclerosis: A randomized, open-label phase 2a study

J Neurol Neuroscience; 16 (03) 2025 : 001-009 • RESEARCH ARTICLE